NCT07435480Not yet recruiting
Irisin Hormone as a Novel Diagnostic Marker for Detection and Progression of Diabetic Nephrophathy Patients
Evaluation of Irisin as a Novel Diagnostic Marker for Early Detection and Progression of Diabetic Nephrophathy
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
Study the relation between irisin level and progression of diabetic nephropathy and its early detection.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 20 Feb 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Sohag University
- NCT number
- NCT07435480
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Apr 2026 to the primary completion date, 1 Mar 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Non-diabetic kidney diseases.
- Acute illness, infection, obesity, hypertension, type 1 DM.
- Malignancy, other endocrine disorders, corticosteroid drugs, pregnancy, lactation.
Who the study is looking for
- Type 2 diabetic patients
Age in the registry: 30 years to 75 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.